SCHEMBL19974568

SCHEMBL19974568

CCOP(=O)(OCC)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@](C)(CO)[C@@H]1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.55
P2RY1 P47900 9/20 0.52
P2RY2 P41231 3/20 0.52
SRC P12931 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
TRPM2 O94759 2/20 0.52
TAS1R3 Q7RTX0 2/20 0.52
TAS1R1 Q7RTX1 2/20 0.52
DNPH1 O43598 1/20 0.52
PRKAB2 O43741 1/20 0.52
LDHA P00338 1/20 0.52
ADRB2 P07550 1/20 0.52
FBP1 P09467 1/20 0.52
ADORA1 P30542 1/20 0.52
PRKAG1 P54619 1/20 0.52
PRKAA2 P54646 1/20 0.52
PDE4D Q08499 1/20 0.52
KCNH2 Q12809 1/20 0.52
PRKAA1 Q13131 1/20 0.52
PDE3A Q14432 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19979029 0.87 ADORA2A (0.57) ADORA2AP2RY1SMN1; SMN2ADORA1PDE4D
SCHEMBL19974418 0.87 ADORA2A (0.57) ADORA2AP2RY1SMN1; SMN2ADORA1PDE4D
SCHEMBL19979252 0.85 P2RX3 (0.51) ADORA2AP2RX3ALDH1A1NT5E
SCHEMBL22700214 0.79 HPGD (0.49) ADORA2ATAS1R3TAS1R1NT5E
SCHEMBL19974575 0.79 ADORA2A (0.43) ADORA2AP2RY1ADORA1P2RY11NT5E
SCHEMBL19975000 0.79 ADORA2A (0.58) ADORA2AP2RY1SMN1; SMN2ADORA1PDE4D
SCHEMBL17109545 0.79 ADORA2A (0.71) ADORA2AP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL19644970 0.79 ADORA2A (0.71) ADORA2AP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL17117148 0.79 ADORA2A (0.71) ADORA2AP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL23790862 0.78 P2RY1 (0.65) ADORA2AP2RY1P2RY2SRCSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11434255-B2 Nucleoside and nucleotide analogues bearing a quaternary all-carbon stereogenic center at the 2′ position and methods of use as a cardioprotective agent LCB PHARMA INC. (CA) 2022-09-06 US disclosed
EP-3512860-B1 NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT LCB PHARMA INC (CA) 2020-11-25 EP disclosed
EP-3512860-A1 NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT LCB Pharma Inc. (CA) 2019-07-24 EP disclosed
WO-2018049534-A1 NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT LCB PHARMA INC. (CA) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11434255-B2 Nucleoside and nucleotide analogues bearing a quaternary all-carbon stereogenic center at the 2′ position and methods of use as a cardioprotective agent TNNT2, NT5C2, PNP ADORA2A 57/4885P2RY1 146/4885P2RY2 198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.